If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

Submission of a tumor sample containing at least 40% tumor is required. Please submit snap-frozen, paraffin-embedded, or OCT-embedded tumor tissue. Submission of a normal (germline) samples is no longer recommended/required for this testing.

Targeted oncology microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations in the tumor to aid in prognosis and treatment assessment. We only accept neuroblastoma and Wilms tumor samples for this test at this time.

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma:

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains will also be detected with the assay

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. At least 40% tumor must be present in the submitted tumor sample. A result from a sample containing <40% tumor may be reported as unsatisfactory (no results reported) if clearly discernible abnormalities are not observed. An internal pathology review will be performed on submitted tumor samples to verify tumor content.
2. Pre-treatment tumor samples are preferred over post-treatment samples. If submitting a tumor sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

Submission of a tumor sample containing at least 40% tumor is required. Please submit snap-frozen, paraffin-embedded, or OCT-embedded tumor tissue. Submission of a normal (germline) samples is no longer recommended/required for this testing.

Targeted oncology microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations in the tumor to aid in prognosis and treatment assessment. We only accept neuroblastoma and Wilms tumor samples for this test at this time.

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma:

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains will also be detected with the assay

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. At least 40% tumor must be present in the submitted tumor sample. A result from a sample containing <40% tumor may be reported as unsatisfactory (no results reported) if clearly discernible abnormalities are not observed. An internal pathology review will be performed on submitted tumor samples to verify tumor content.
2. Pre-treatment tumor samples are preferred over post-treatment samples. If submitting a tumor sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma:

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains will also be detected with the assay

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. At least 40% tumor must be present in the submitted tumor sample. A result from a sample containing <40% tumor may be reported as unsatisfactory (no results reported) if clearly discernible abnormalities are not observed. An internal pathology review will be performed on submitted tumor samples to verify tumor content.
2. Pre-treatment tumor samples are preferred over post-treatment samples. If submitting a tumor sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.

If you are an external healthcare provider with no access to Nationwide Children's Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children's Epic system, no requisition form is required; please place the lab order electronically in Epic. Please send all samples via overnight delivery. Saturday deliveries are accepted; please check Saturday Delivery on shipment label.

If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory.

Submission of a tumor sample containing at least 40% tumor is required. Please submit snap-frozen, paraffin-embedded, or OCT-embedded tumor tissue. Submission of a normal (germline) samples is no longer recommended/required for this testing.

Targeted oncology microarray analysis is performed on the Affymetrix OncoScan(TM) CNV platform to detect clinically significant chromosomal aberrations in the tumor to aid in prognosis and treatment assessment. We only accept neuroblastoma and Wilms tumor samples for this test at this time.

Neuroblastoma:

This test evaluates the following clinically significant aberrations within the cancer genome for Neuroblastoma:

• Copy number loss of 1p, 3p, 4p and 11q
• Copy number gain of 1q, 2p and 17q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 3p, 4p and 11q
• MYCN and ALK gene amplification or copy gain
• Whole chromosome gains will also be detected with the assay

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

Wilms Tumor:

This test evaluates for the following clinically significant aberrations within the cancer genome for Wilms Tumor:

• Copy number loss of 1p, 11p13, 11p15, 16q, and 17p
• Copy number gain of 1q
• Copy-Neutral Loss of Heterozygosity (CN-LOH) involving 1p, 11p13, 11p15, 16q, and 17p

Although this is primarily a targeted assay for aberrations of established clinical significance, other genomic copy number aberrations and LOH with emerging significance may be reported.

PLEASE NOTE:

1. At least 40% tumor must be present in the submitted tumor sample. A result from a sample containing <40% tumor may be reported as unsatisfactory (no results reported) if clearly discernible abnormalities are not observed. An internal pathology review will be performed on submitted tumor samples to verify tumor content.
2. Pre-treatment tumor samples are preferred over post-treatment samples. If submitting a tumor sample collected during or after treatment (e.g. post-chemotherapy), please indicate post-treatment status of the sample on the requisition form.
3. An FFPE tissue block is preferred over FFPE tissue scrolls. If submitting FFPE tissue scrolls, an H&E slide from a consecutive cut is also required Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required. Tissue blocks can be returned to the treating institution upon request.